OptimizeRx (NASDAQ:OPRX) Rating Reiterated by JMP Securities

OptimizeRx (NASDAQ:OPRX - Get Free Report)'s stock had its "market outperform" rating reiterated by equities researchers at JMP Securities in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $15.00 target price on the stock. JMP Securities' price objective would suggest a potential upside of 50.60% from the company's previous close.

A number of other analysts have also recently weighed in on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $17.00 price target on shares of OptimizeRx in a research report on Monday, April 1st. Barclays started coverage on shares of OptimizeRx in a report on Wednesday, January 3rd. They issued an "equal weight" rating and a $15.00 price objective on the stock. Finally, Stifel Nicolaus reiterated a "buy" rating and issued a $13.00 price objective on shares of OptimizeRx in a report on Monday, April 1st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, OptimizeRx currently has an average rating of "Moderate Buy" and an average price target of $15.86.

OptimizeRx Stock Performance

OptimizeRx stock traded down $0.36 during trading on Tuesday, reaching $9.96. 202,775 shares of the company's stock were exchanged, compared to its average volume of 118,596. The company's 50-day moving average is $13.59 and its two-hundred day moving average is $11.98. OptimizeRx has a 52-week low of $6.92 and a 52-week high of $16.65. The firm has a market cap of $180.77 million, a price-to-earnings ratio of -12.45 and a beta of 0.98.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in OptimizeRx by 2.9% in the 4th quarter. Vanguard Group Inc. now owns 1,021,002 shares of the company's stock worth $14,611,000 after purchasing an additional 28,416 shares during the last quarter. Greenwood Capital Associates LLC grew its position in OptimizeRx by 58.8% in the 4th quarter. Greenwood Capital Associates LLC now owns 54,675 shares of the company's stock worth $782,000 after purchasing an additional 20,245 shares during the last quarter. Barclays PLC grew its position in OptimizeRx by 688.1% in the 4th quarter. Barclays PLC now owns 22,170 shares of the company's stock worth $317,000 after purchasing an additional 19,357 shares during the last quarter. Nuveen Asset Management LLC grew its position in OptimizeRx by 25.2% in the 4th quarter. Nuveen Asset Management LLC now owns 44,035 shares of the company's stock worth $630,000 after purchasing an additional 8,857 shares during the last quarter. Finally, Occudo Quantitative Strategies LP bought a new position in OptimizeRx in the 4th quarter worth about $286,000. Institutional investors own 76.47% of the company's stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.